Skip to main content
EyeGene,Inc logo

EyeGene,Inc — Investor Relations & Filings

Ticker · 185490 ISIN · KR7185490000 KO Professional, scientific and technical activities
Open in API
Filings indexed 314 across all filing types
Latest filing 2026-01-13 Regulatory Filings
Country KR South Korea
Listing KO 185490

About EyeGene,Inc

https://eyegene.co.kr/en/

EyeGene, Inc. is a clinical-stage biopharmaceutical company that researches and develops innovative therapeutics, with a primary focus on gene and cell therapy for age-related diseases. The company's pipeline includes EG-Mirotin, a treatment candidate for non-proliferative diabetic retinopathy and dry age-related macular degeneration. EyeGene is also developing preventive vaccines, such as EG-HPV for cervical cancer, utilizing its proprietary EG-Vac adjuvant system to enhance vaccine efficacy. The company is dedicated to creating transformative treatments by advancing biomedical science.

Recent filings

Filing Released Lang Actions
불성실공시법인지정예고 (공시변경)
Regulatory Filings Classification · 95% confidence The document is a formal notice from the Korea Exchange (KOSDAQ) regarding the 'pre-designation of an unfaithful disclosure corporation' (불성실공시법인지정예고). This is a regulatory notification concerning a company's failure to comply with disclosure requirements, which falls under general regulatory announcements and does not fit into specific categories like financial reports or shareholder communications. Therefore, it is classified as a Regulatory Filing (RNS).
2026-01-13 Korean
투자판단관련주요경영사항 (대상포진 백신 EGHZ 국내 기술이전 계약 해지 및 권리 정리)
Legal Proceedings Report Classification · 95% confidence The document is a regulatory filing from the Korean Exchange (KRX) system regarding a 'Major Management Matter' (투자판단 관련 주요경영사항). It details the termination of a technology transfer agreement for a shingles vaccine. Since this is a specific corporate announcement regarding a material business event (contract termination) that does not fit into categories like M&A, financial reports, or director dealings, it falls under the general regulatory filing category.
2025-12-29 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the shareholding changes of an executive (Yoo Won-il) at Eyegene Inc. This type of filing is a standard regulatory requirement for directors and major shareholders to disclose their personal transactions in company securities, which corresponds to the 'Director's Dealing' category.
2025-12-18 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the shareholding changes of an executive (Rhee Myeong Jae) at Eyegene Inc. This type of filing is a standard regulatory requirement for insider trading/shareholding disclosures, which corresponds to the 'Director's Dealing' category.
2025-12-18 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard regulatory filing in South Korea (often referred to as a 'Section 16' equivalent in the US) where company insiders report changes in their shareholdings. Based on the provided definitions, this falls under 'Director's Dealing' (DIRS), which covers personal share transactions by company directors and executives.
2025-12-18 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 98% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities (Financial Supervisory Service/Korea Exchange). This type of filing is a standard regulatory disclosure for major shareholders or insiders reporting changes in their equity holdings, which falls under the category of 'Major Shareholding Notification' (MRQ) as it details the acquisition/disposal of shares by a major shareholder (BMI Korea) in the issuer (Eyegene).
2025-12-18 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.